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Epigenetic alterations are necessary for the establishment of functional and phenotypic 
diversity in the populations of immune cells of the monocytic lineage. The epigenetic 
status of individual genes at different time points defines their transcriptional responses 
throughout development and in response to environmental stimuli. Epigenetic states 
are defined at the level of DNA modifications, chromatin modifications, as well as at 
the level of RNA base changes through RNA editing. Drawing from lessons regarding 
the epigenome and epitranscriptome of cells of the monocytic lineage in the periphery, 
and from recently published RNAseq data deriving from brain-resident monocytes, 
we discuss the impact of modulation of these epigenetic states and how they affect 
processes important for the development of a healthy brain, as well as mechanisms of 
neurodegenerative disease and aging. An understanding of the varied brain responses 
and pathologies in light of these novel gene regulatory systems in monocytes will lead to 
important new insights in the understanding of the aging process and the treatment and 
diagnosis of neurodegenerative disease.
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iNTRODUCTiON
The mononuclear phagocyte system is a branch of the leukocyte family comprising macrophages, 
dendritic cells (DC), tissue macrophages, and microglia and their multiple subsets. While their 
diverse tissue and immune-specific functions have been the subject of much discussion and debate, 
the developmental origin of these cells remains largely undetermined (1).
Cells that give rise to the mononuclear phagocyte system are embryonically derived from “blood 
islands” during embryonic development (2, 3). After development, common myeloid precursors 
derive from hematopoietic cells within the bone marrow, and egress into the bloodstream to migrate 
to the site of infections, where they differentiate into effector immune cells such as macrophages and 
DC. The origin of resident tissue macrophages and brain-resident monocytic cells is still controver-
sial. Within the steady-state CNS, the origin, function, and turnover of subsets of monocytic cells, 
often collectively referred to as “microglia,” is a constantly evolving area of study, particularly due to 
issues defining this heterogeneous group as a single population. Until recently, it was thought that 
these were the only cell population, which performed immune surveillance in the brain, given that 
surveillance by peripheral monocytic leukocytes was considered limited at best. However, a recent 
FiGURe 1 | Photomicrograph showing eYFP/CD11c+ cells (black 
arrows) in discreet regions of the adult steady-state CNS. EYFP/
CD11c+ cells are evident along the rostral migratory stream (white arrows), 
lining the subventricular zone of the lateral ventricles, the subgranule cell layer 
of the hippocampus, and within the circumventricular organs. The 
photomicrograph is illustrative of the data published by Bulloch et al. (5).
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study showed the presence of lymphatic vessels within the CNS 
demonstrating clear routes for leukocyte trafficking in and out of 
the brain (4). Additionally, studies of transgenic mice that express 
fluorescent protein markers for monocytic cells, in particular DC, 
clearly showed the presence of these leukocytes traversing dis-
crete regions of the steady-state brain (Figure 1) (5). In multiple 
studies examining various immune challenges, results show that 
this EYFP+ cell population is comprising both peripherally and 
centrally derived monocytic cells with diverse functions (6–10).
Taken together, these findings demonstrate the CNS is subject 
to far greater immune surveillance than previously believed. 
This concept opens up new possibilities to define the func-
tion of monocytic cells in the brain and understand the vastly 
complicated relationship between cells of monocytic lineage 
and underlying etiologies of CNS neuropathology. The field of 
epigenetic regulation of immune function is one such area that 
begs further exploration, especially within the brain. The follow-
ing will introduce this area and present what is currently known 
about this regulation in the context of CNS/immune function.
DNA MeTHYLATiON AND 
DeMeTHYLATiON
DNA methylation is an epigenetic modification of genes that 
regulates genomic imprinting, X chromosome inactivation, cell 
fates during development (11), chromosomal stability, repression 
of transposable elements, and gene expression during the lifetime 
of the organism (12, 13). The majority of DNA methylation in 
mammalian genomes takes place within a CpG dinucleotide con-
text (generating 5-methyl-CpG, or meCpG). However, meCpH 
methylation (where H = dA, dC, or dT) is also known to occur, 
notably in the adult mammalian brain (14).
Generally, the quantity of CpG methylation is inversely 
correlated with gene expression. CpG methylation can control 
transcription either locally [e.g., by occluding transcription factor 
binding sites within promoter regions (15) or by binding DNA 
within gene bodies and interfering with transcriptional elonga-
tion (14)] or globally (where methylation of CpG rich regions can 
lead to the recruitment of proteins that alter the chromatin state 
and result in general locus silencing). However, overall rules by 
which mCpG (or indeed hmCpG or mCpH) control transcrip-
tion are not clear and attempts at generalizing specific findings 
are often controversial.
Recently, it has been convincingly demonstrated that DNA 
methylation can be reversed. Direct demethylation is not ener-
getically favorable; thus, demethylation occurs in a number of 
steps, either through the direct deamination of meCpG to TpG 
and removal of the T:G mismatch by thymine DNA glycosylase 
(TDG)/Gadd45 (16–18) or through the enzymatic oxidation of 
meCpG to hmCpG (catalyzed by the TET family of proteins) and 
removal of the hydroxymethyl moiety through catabolism (for-
mylation and carboxylation) and excision through DNA repair 
that again involves TDG (19).
Demethylation is crucial during development, to “erase” 
any paternal or maternal marks in the zygote, which are then 
“reset” by specific methyltransferases during imprinting, and 
remain grossly stable thereafter, in the vast majority of tissues. 
However, tissue-specific differentiation is associated with 
significant, if subtle, changes in the DNA methylome, and sets 
of “differentially methylated regions” or DMRs are known to 
be associated with plasticity and developmental changes. Some 
of these changes are rather dramatic: demethylation of a single 
open reading frame within a large imprinted region in astrocyte 
niches (leading to temporally restricted, bi-allelic expression of 
the Dlk1 gene) is essential for neurogenesis (20). Conversely, 
disturbances in imprinting implicate Dlk1 as a novel risk gene 
for experimental autoimmune encephalomyelitis (EAE) in mice 
(21). Most changes, however, are far less robust and result in levels 
of heterogeneity in patterns of DNA methylation (both hypo and 
hyper methylation of DMRs) that are much harder to link to clear 
mechanistic consequences.
Limited information is available about the DNA methylome 
in monocytes, or its plasticity during developmental transitions, 
such as differentiation from multipotent progenitors (MPP), line-
age commitment, and aging (22, 23). Study by Ji and colleagues 
used comprehensive high-throughput array-based relative 
methylation (CHARM) analysis and revealed striking epigenetic 
plasticity, resulting in increased overall methylation upon lym-
phoid relative to myeloid commitment. Most DMRs distinguish-
ing MPP cells from common lymphoid progenitors (CLP) lost 
methylation during this step of early lymphoid commitment. In 
contrast, in common myeloid progenitors (CMP) in the earliest 
step of myeloid commitment displayed substantially more hyper-
methylated than hypomethylated DMRs. Interestingly, at the next 
step of lineage commitment, both of these trends were reversed 
and 15-fold more DMRs showed gain of methylation upon the 
transition from CLP to DN1, and nearly all DMRs showed loss 
of methylation on transition from CMP to GMP. Comparing 
DN1 to GMP, two populations similarly differentiated toward 
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lymphoid and myeloid fates, respectively, there were eightfold 
more DMRs with higher-level methylation in DN1 cells, suggest-
ing a skewing toward greater methylation in lymphoid compared 
to myeloid hematopoiesis. These observations were in concert 
with data obtained from Dnmt1-hypomorphic mice (which are 
unable to maintain CpG methylation properly) showing normal 
myeloid, but diminished lymphoid development (24). Moreover, 
inhibiting DNA methylation in in  vitro system using 5-aza-
29-deoxycytidine promotes myeloid versus lymphoid specifica-
tion, providing a mechanism for the myeloid skewing observed 
in Dnmt1 hypomorphs.
Nothing is known about the status of methylation in cells of the 
monocytic lineage in the brain (bDCs or microglia). Generally, 
what is known comes from a handful of studies of monocyte to DC 
differentiation in vitro (25) or human monocyte to macrophage 
differentiation in vivo, in the context of pregnancy (26). In vitro, 
regions around specific demethylated CpGs could be associated 
with alterations in transcription factor binding sites for factors 
important to maturation (e.g., Jun, Bcl11a in the monocyte to 
DC transition), resulting in robust changes in methylation of a 
handful of promoters (SRC, PLEKHG6, and ITGB2), which were 
in turn correlated with increased transcription. In vivo, similar 
pattern changes are also visible in the monocyte to macrophage 
comparison, where the small magnitude of changes (e.g., 25% 
decrease in methylation in the Lag3 promoter, or 50% increase in 
the Ilib promoter) results in substantial transcriptional changes, 
through mechanisms that are not immediately obvious.
However, mild or mechanistically unclear, methylation 
changes in DNA in macrophages have been associated with 
inflammation [e.g., pathogen infection (27) or environmental 
changes – e.g., smoking (28)], memory to infection [e.g., endo-
toxin tolerance (29)], and aging (23). Though currently methyl-
ome maps are not available for cells of the monocytic lineage in 
the brain, it is expected that these will be different within differ-
ent cell subsets or types (i.e., microglia, macrophage, and bDC), 
and will produce distinct patterns under different conditions. 
Conversely, mild differences in methylation or demethylation 
mediators [e.g., deaminases such as AID or APOBEC2 – (16), 
or hydroxylases such as the TET family of proteins] might 
result in patterns “at risk” for disease, or alter disease onset and 
manifestations (30).
HiSTONe MODiFiCATiON
While cytokines and chemokines are believed to be initially 
responsible for inducing monocyte development in the adults, 
every phase of monocytic differentiation is ultimately regulated 
by a specific set of transcription factors, which confer proper 
expression of lineage-specific genes at the appropriate time dur-
ing development and differentiation or in response to immune 
challenge. Histone modifications and chromatin remodeling are 
evolutionarily conserved regulatory mechanisms that can repress 
of facilitate gene expression in response to environmental and 
developmental stimuli (31). Post-translational modifications of 
histone proteins, which are major constituents of chromatin, 
include acetylation, methylation, phosphorylation, ubiquitina-
tion, ribosylation, and sumolation. Such modifications have 
been shown to affect chromatin structure and make regulatory 
sequences more or less accessible for transcription factor and 
co-factor binding. As a result, covalent modifications of histone 
proteins have a major impact on the gene expression (31). 
Another important characteristic of histone modifications is their 
dynamic nature and responsiveness to environmental changes, 
which places them at the interface of genes and environment. 
Thus, it is not surprising that histone modifications have been 
shown to regulate the migration and differentiation of monocyte-
derived cells in response to injury and infection (29).
Histone modifications have been shown to affect an impor-
tant step in monocyte-mediated immune function, which is 
migration to the site of inflammation and to the lymph nodes. 
Signaling through chemokine receptors, such as CCR2, CCR5, 
and CCR7, and the expression of their ligands are critical for the 
proper immune response (32). For example, CCL2, also referred 
to as monocyte chemoattractant protein-1 (MCP-1), is involved 
in directing the egress of monocytes into the bloodstream and 
their migration to the sites of inflammation (33, 34). Excessive 
CCL2 secretion has been linked to many inflammatory diseases, 
whereas a lack of expression severely impairs immune respon-
siveness (35).
Under non-inflammatory conditions, the Ccl2 locus is tran-
scribed at low level, but rapid induction of gene expression occurs 
on exposure of cells to various proinflammatory stimuli. NF-kB 
transcription factor has been shown to be the master regulator of 
LPS-induced activation of CCL2 and recent report demonstrate 
that the coactivator, IkBz, is also critical for the expression of 
this chemokine in the macrophages (36). Specifically, the direct 
recruitment of IkBz to the proximal promoter of Ccl2 and induc-
tion of H3K4 trimethylation seem to be required for the produc-
tion of CCL2 in macrophages, since IkBz-deficient macrophages 
exhibited impaired secretion of CCL2 when challenged with 
LPS or peptidoglycan. Additionally, IkBz-deficient mice showed 
significantly impaired CCL2 secretion and monocyte infiltration 
in an experimental model of peritonitis (36).
An interesting mode of regulation has been described for 
another chemokine receptor gene, Ccr5. Although monocytes 
display high levels of CCR5, the expression is lost as cells start to 
differentiate into macrophages and DC. Such rapid downregu-
lation of Ccr5 expression is believed to be achieved because of 
multivalent chromatin state characteristic of its promoter (37). 
Specifically, it has been shown that Ccr5 promoter is covered 
with high levels of activating histone mark, AcH3, as well as 
relative high levels of repressive modifications, H3K9me3 and 
H3K27me3. Moreover, the histone modifications in monocytes 
are accompanied by relatively high levels of DNA methylation 
of Ccr5 promoter. The fact that monocytes display high amounts 
of repressive marks in conjunction with histone acetylation may 
reflect the potential to rapidly shut down Ccr5 transcription upon 
differentiation.
Repressive histone modification, H3K27me3, has also been 
shown to accumulate at the promoter of Ccr7 gene in monocyte-
derived DC but not in conventional DCs (38). As a result, moDCs 
express very low levels of CCR7 and do not migrated to lymph 
nodes as effectively as cDCs following inhaled allergen challenge. 
This example demonstrates how histone modification of the 
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chemokine receptor can control the migration and therefore the 
function of monocyte-derived DCs in vivo.
After arriving at the site of infection, monocytic cells differ-
entiate into effector cells, such as DC and macrophages. A well-
orchestrated gene expression program is necessary to activate 
lineage-specific genes and at the same time repress transcripts 
characteristic of progenitors. A genome-wide mRNA expression 
profile and map of three major histone modifications (AcH3 and 
H3K4me3-permissive and H3K27me3-repressive mark) associ-
ated with gene expression in monocytes, macrophages, and DCs 
have demonstrated that specific sets of histone modifications are 
employed to execute such transcriptional programs (39). For 
example, during differentiation, the H3K4me3 levels decreased 
on monocyte-specific CD14, CCR2, and CX3CR1 but increased 
on DC-specific TM7SF4/DC-STAMP, TREM2, and CD209/
DC-SIGN genes as well as genes associated with phagocytosis 
and antigen presentation. Moreover, in macrophages and DCs, 
H3K4me3 levels increased in a large genomic cluster of proin-
flammatory and chemotactic CC chemokines on chromosomes 
17q11.2 and 16q13.
Another study has demonstrated the role of H3K4 methyla-
tion in the expression of specific proinflammatory cytokines in 
macrophages. Xia and colleagues (40) have shown that Ash1l, a 
H3K4 methyltransferase, suppressed interleukin-6 (IL-6), and 
tumor necrosis factor (TNF) production in toll-like receptor 
(TLR)-triggered macrophages, protecting mice from sepsis. 
Moreover, Ash1l-silenced mice were more susceptible to autoim-
mune disease as a result of enhanced IL-6 production. Further 
analysis revealed that Ash1l induced H3K4me modification 
at the Tnfaip3 promoter via its methyltransferase activity thus 
controlling innate IL-6 production and suppressing inflamma-
tory autoimmune diseases, providing mechanistic insight into 
epigenetic modulation of immune responses and inflammation.
Histone modification plays the role not only in differentiation 
of macrophages but also in polarization of their phenotype into 
M1 and M2 subtypes. Whereas M1 macrophages are proinflam-
matory, M2 macrophages are associated with response to anti-
inflammatory reactions and tissue remodeling. Deletion of histone 
deacetylase HDAC9 in an atherosclerosis mouse model (LDLr−/−, 
low density lipoprotein receptor knock out) reduced atheroscle-
rosis and resulted in polarization of macrophages toward M2-like 
phenotype as well as upregulation of lipid homeostatic genes and 
downregulation of inflammatory genes (41). The upregulation 
of M2 and downregulation of M1 genes in HDAC9-deficient 
macrophages were hypothesized to be through PPAR-γ pathway 
since the expression of PPAR-γ in double KO macrophages was 
increased compared with single KO macrophages and quantita-
tive ChIP assays demonstrated increased levels of total H3, H4, 
H3K9 at the promoter of PPAR-γ. These experiments support the 
concept that increased HDAC9 expression in macrophages may 
be atherogenic via suppression of cholesterol efflux and genera-
tion of alternatively activated M2 macrophages.
M2-macrophage activation is mediated by IL-4 and/or IL-13 
and is associated with parasite infections and allergic inflamma-
tion. It has been shown that continuous IL-4 signaling leads to 
transcriptional activation of STAT6 and subsequent increase in 
the levels of demethylase Jmjd3 (42). As a result, increased Jmjd3 
contributes to the decrease of inhibitory H3K27me2/3 marks at 
the promoter of M2 marker genes and promote M2 phenotype. 
The authors confirmed the decrease in H3K27me2/3 and increase 
in Jmjd3 recruitment to M2 marker genes by in vivo studies using 
a Schistosoma mansoni egg-challenged mouse model, a well-
studied system known to support an M2 phenotype.
The same immune challenge was used to demonstrate the role 
of HDAC3 in M2 polarization (43). HDAC3 binds genome-wide 
and acts at a subset of IL-4 target gene enhancers to restrict 
deposition of activating histone marks. Macrophages lacking 
histone HDAC3 display a polarization phenotype similar to IL-4-
induced alternative activation and are hyperresponsive to IL-4 
stimulation. In addition, exposure to Schistosoma mansoni eggs 
of mice lacking HDAC3 prevented development of pulmonary 
inflammation. Interestingly, HDAC3-deficient macrophages 
display deficit in response to LPS and are unable to activate the 
expression of large number of inflammatory genes normally 
upregulated by LPS (44).
Lysine demethylase JMJD3 has also been shown to be involved 
in the inflammatory response. In macrophages, JMJD3 expression 
is rapidly induced by proinflammatory stimuli, and it is recruited 
to the transcription start sites (TSSs) of LPS-induced genes, where 
it participates directly in the transcriptional response (45, 46). To 
demonstrate whether this activation of transcription is achieved 
through the demethylation of H3K27me3 at target gene promoters, 
Kruidenier and colleagues developed and used selective JMJD3 
inhibitors GSK-J4 and GSK-J5 to modulate LPS-induced immune 
response in human primary macrophages. Administration of 
GSK-J4 significantly reduced the expression of ~50% of LPS-
driven cytokines as assessed by PCR array, including TNF-α. In 
addition, chromatin immunoprecipitation (ChIP) studies con-
firmed that GSK-J4, but not GSK-J5, prevented the LPS-induced 
loss of H3K27me3 associated with the TNF-α TSS and blocked the 
recruitment of RNA polymerase II to this locus (47).
Several studies have explored the therapeutic potential of 
HDAC inhibitors as anti-inflammatory agents. Both in vivo and 
in  vitro, various HDAC inhibitors, suberoylanilide hydroxamic 
acid (SAHA), trichostatin A (TSA), and sodium valproate (VPA) 
have been shown to block the secretion of proinflammatory 
cytokines, such as TNF-α, IL-1, IL-6, and IL-12.
Moreover, HDAC inhibitor administration to mice was found 
to ameliorate the autoimmune manifestations of graft-versus-host 
disease, systemic lupus erythematosus, concanavalin A-induced 
hepatitis, EAE, rheumatoid arthritis, and colitis (48–51). On a 
mechanistic level, Nenconi and colleagues demonstrated that 
HDAC inhibitors, sodium VPA and MS-275, interfered with DC 
differentiation from monocytic cells (52). DCs exposed to HDAC 
inhibitors have reduced expression of CD1a, a DC hallmark, CD80 
and CD40, costimulatory molecules, and CD83, which is typically 
expressed on mature DCs. Consistent with anti-inflammatory 
function of HDAC inhibitors, the treatment profoundly impaired 
the DC secretion of the proinflammatory cytokines TNF-α and 
IL-6, IL-12 as well as IL-10 production. Finally, DCs grown in the 
presence of VPA or MS-275 had impaired immunostimulatory 
capacity and migration to CCL19.
Recently, the concept of “trained immunity” was introduced, 
which postulates that innate immune responses launched 
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against initial infection may afford protection against reinfec-
tion. The evidence for such “trained immunity” was provided 
by infecting mice lacking functional T and B lymphocytes (to 
rule out the contribution of adaptive immunity) with Candida 
albicans and demonstrating protection against reinfection in 
a monocyte-dependent manner (53). Monocyte training by 
fungal cell wall β-glucans was associated with stable changes 
in global histone trimethylation H3K4, but not of H3K27me3. 
Genome-wide RNA-seq analysis following β-glucan treat-
ment confirmed a strong correlation between the increase in 
H3K4me3 occupancy and the increase in gene expression. 
More specifically, H3K4me3 was elevated at the promot-
ers of important target genes such as the proinflammatory 
cytokines TNF-α, IL-6, and IL-18 after β-glucan treatment 
and subsequently, increased gene transcription of TNF-α and 
IL-6 mRNA upon restimulation was observed (53). These 
data clearly demonstrate the important role of stable and 
long-lasting histone modification in the “trained immunity.” 
Moreover, it has been demonstrated that “endotoxin tolerance,” 
a form of innate memory in which the initial stimulation of 
monocytes or macrophages with the TLR4 ligand LPS causes 
these cells to enter a long-term refractory state, also depends on 
H3K4me3 epigenetic mark (54). The restimulation of tolerant 
macrophages with LPS produces two different gene-expression 
profiles: one set of “tolerized” genes show diminished or abol-
ished expression, whereas the expression of a second group 
of “non-tolerized” genes is increased or remains unchanged. 
Although the transcription-activating H3K4me3 and H4Ac 
marks are present on the promoters of both tolerized and non-
tolerized genes, following reinfection they are only maintained 
on the promoters of the non-tolerized genes whereas the toler-
ized genes, including those encoding inflammatory cytokines, 
remain devoid of this mark (54).
Together, these examples demonstrate that the ability of mono-
cytic cells to migrate to the site of infection and differentiate into 
effector cells in response to environmental cues greatly depends 
on their capacity to rapidly upregulate or shut down large sets 
of genes. Proper regulation of chromatin states through histone 
modifications is critical in executing these functions.
RNA DYNAMiCS
RNA metabolism is a complex process that encompasses RNA 
transcription, pre-mRNA processing/splicing, transport, loca-
tion, stability, and/or translation of mature mRNAs and mRNA 
decay. Epigenetic regulatory mechanisms in RNA metabolism 
are known to orchestrate virtually all steps of the mRNA life 
cycle ranging from pre-mRNA splicing to mRNA degradation. 
Remarkably, these regulators can coordinate the expression 
pro-inflammatory and anti-inflammatory molecules to initiate, 
maintain, and resolve immune response in monocytic cells (55, 
56). These epigenetic processes are controlled by numerous 
regulators, including microRNA (miRNA), long non-coding 
RNA (lncRNA), RNA-binding proteins (RBP), and RNA editing 
enzymes (57–59). These regulators can promote mRNA stabiliza-
tion/degradation or prevent mRNA translation. In the following, 
we will discuss the role of miRNA, lncRNA, RBPs, and RNA 
editing enzymes as epigenetic regulators, and the role of RNA 
metabolism in cells of monocytic lineage.
microRNA
microRNAs are potent new players in epigenetic regulation. miR-
NAs can respond quickly to environmental stimulation and act to 
regulate many different systems. For example, miR-27a has been 
shown to be involved in changes in monocyte differentiation fol-
lowing incidents of high alcohol consumption (60). In this study, 
healthy volunteers showed significant changes in the populations 
of circulating monocytes and these changes were replicated 
in  vitro in the presence of alcohol. Alcohol-mediated miR-27a 
upregulation led to polarization and activation of circulating 
monocytes.
The vast variety of different miRNAs can have diverse effects 
upon cells of monocytic lineage. miR-124 can suppress the 
immune response in microglia by modulating P65 activation. 
Interestingly (61), miR-124 is also responsive to the environment: 
its strongest phenotype is the result of long-term opioid treatment. 
The NF-kB pathway can be silenced by the expression of miR-203 
in microglia (62). Suppression of this pathway can protect against 
microglial death and degeneration after brain injury and could 
potentially be a target of therapies aimed at reducing the effects 
of neurodegenerative diseases.
The modulation of macrophage phenotype is important for 
their proper function; dysregulation of their phenotype can 
contribute or even cause pathological conditions and damage. 
The role of miRNA in the regulation of the switch from the M1 
inflammatory and M2 repair phenotypes in macrophages is 
only recently coming to light. miR-21 has been shown to be an 
important player in the pathway that causes this switch. It acts to 
regulate the proinflammatory response and can inhibit the NF-kB 
pathway through interaction with the colony-stimulating factor 
(CSF) pathway (63). miRNAs also play a role in the recruitment 
of macrophages themselves. miR-26a also acts upon the CSF and 
prevents the recruitment of macrophages in a hepatocellular 
carcinoma cell line (64).
There is increasing evidence that miRNAs play a key role in 
the progression of Alzheimer’s disease (AD). Further explora-
tion into the role of miRNAs in AD could lead to novel models 
and eventual treatments. One of the most promising miRNAs 
involved in AD is miR-155 (65). It has been shown to be a key 
regulator of T lymphocyte function during inflammation. Mice 
lacking miR-155 are shown to have reduced T cell-mediated 
immune responses, and T cells from these animals are more 
likely to be Th2 cells that act to reduce the proinflammatory 
response. T cell infiltration of the brain is one of the key dysfunc-
tions in the progression of AD. In the 3xtg triple transgenic AD 
model mouse, upregulation of miR-155 has been linked with an 
increase in the severity of the AD phenotype (66). This event 
appeared at the very beginning of the onset of AD, before the 
appearance of plaques and concurrently with the activation of 
microglia and astrocytes. Assessing activation at this early stage 
could be used as a diagnostic tool. Some success with miR-155 
targeting has been reported in the SOD1 mouse, a model for 
amyotrophic lateral sclerosis (ALS). Targeting of miR-155 con-
tributed to the reduction of inflammation and a corresponding 
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reduction in the severity of the phenotype (67). This provides 
encouraging evidence that miR-155 may be a key player in 
many different neurodegenerative diseases beyond ALS and 
AD. miRNAs will prove to be fertile ground for the study of 
neurodegenerative diseases far into the future.
Long Non-Coding RNA
Broadly defined, lncRNAs are RNA transcripts, which are more 
than 200 nt long and do not code for proteins, and are usually 
found near protein-coding regions. An excellent review by Kung 
and colleagues categorizes lncRNAs based on their genomic 
context, although they are quick to note that these categorizations 
do not provide much information on function or history of the 
lncRNA (68). It is these diverse functions that make the subject of 
lncRNA so interesting to researchers, with recent reviews cover-
ing the role of lncRNA in cancer (69), aging in the brain (70), and 
autoimmune disease (71). This section of the review summarizes 
the role of lncRNAs as they pertain to monocytes in steady state 
and inflammation.
While a host of factors control the complex process of cell dif-
ferentiation, some researchers have identified specific lncRNAs 
that are essential to the differentiation of monocytes into their 
functional descendants. For example, in order for DC to differ-
entiate from monocytes, the lncRNA lnc-DC needs to activate 
signal transducer and activator of transcription 3 (STAT3), a 
transcription factor (72). Lentivirus-mediated RNA interference 
to knockdown lnc-DC caused a downregulation of many genes 
related to DC function and caused the monocyte marker CD14 
to be upregulated in these DC. In the cell line U937, a model 
human cell line in which monocytes can be differentiated into 
macrophages with the application of phorbol myristate acetate 
(PMA), cells with the lncRNA P50-Associated COX-2 Extragenic 
RNA (PACER) knocked down do not differentiate into mac-
rophages upon treatment (73). PMA-treated knocked down cells 
also had an attenuated response to LPS compared to PMA-treated 
controls. PACER was shown to control the cyclooxygenase 2 
(COX-2) gene, whose overexpression is implicated in a variety 
of cancers. Zhang and colleagues found that the lncRNA HOX 
antisense intergenic RNA myeloid 1 (HOTAIRM1) affects the 
transcription of HOXA genes, which impacts the expression 
of CD11b and CD18, genes that are hallmarks of granulocyte 
maturation (74). lncRNA may be involved in the widely studied 
phenomenon of changes in monocyte genomic transcription in 
response to inflammation. Illott and colleagues (75) found that 
LPS stimulation of human monocytes caused 221 lncRNAs to be 
differently expressed. Knockdown of enhancer regions associ-
ated with some of these transcripts caused attenuation of the 
LPS-induced release of proinflammatory IL1b and CXCL8. It has 
also been shown that THRIL (TNFα and hnRNPL related immu-
noregulatory LincRNA) regulates the expression of TNFalpha 
in THP1 macrophages (76). Reddy and colleagues found that in 
diabetic mice, the lncRNA E330013P06 (E33) is upregulated in 
macrophages. In an in vitro study, macrophages overexpressing 
E33 and exposed to LPS expressed more IL-6, TNF, CD36, and 
CCL2 than controls (77) Thus, this lncRNA is part of a positive 
feedback loop of increasing inflammation in a disease model. 
This illustrates the potential for lncRNA as a target for therapies.
With next generation sequencing techniques creating a huge 
volume of data on lncRNA, it is becoming increasingly possible 
to filter signal from noise. Future researchers will thus be able to 
design in depth studies on function of these unique RNAs.
RNA-Binding Proteins
Monocytic cells contain a diverse repertoire of RBPs that govern 
the fate of transcripts by mediating mRNA processing (55). The 
RBPs control mRNA stability and translation in response to 
various stimuli (e.g., developmental signaling, stress, and immune 
challenges) through selective interaction with 3′ untranslated 
regions (UTR) of their target mRNA (55, 56). In monocytic cells, 
these RBP–RNA complexes (ribonucleoprotein complexes; RNP 
complexes) provide more rapid and flexible gene expression for 
inflammation through post-transcriptional regulation.
RNA-binding protein complexes are composed of transcripts 
that contain adenine and uridine-rich elements (AREs) and the 
proteins that bind the AREs (ARE–RBPs) (78, 79). AREs recruit 
many ARE–RBPs that modulate the stability of target mRNAs, 
and their translation. Each ARE–RBP has a distinct regulatory 
function on mRNA stability and translation in cells of monocytic 
lineage. For example, tristetraprolin (TTP) destabilizes mRNA 
of TNF-α and inhibits TNF-α production in LPS-stimulated 
macrophages (80, 81). In contrast, human antigen R (HuR) 
increases TNF-α mRNA stability and reduces its translation in 
LPS-stimulated macrophages by interfering with the functions 
of T-cell-restricted intracellular antigen 1 (TIA-1) and TTP (82). 
Moreover, AU-binding factor 1 (AUF-1) deficiency enhanced 
macrophage recruitment to the sites of inflammation without 
direct degradation of target mRNA (56, 83). These results imply 
a distinct regulatory role of the ARE–RBP complex in the coor-
dination of the stability and translation of mRNA in monocytic 
cells.
In addition to ARE–RBPs complexes, the interferon (IFN)-
γ-activated inhibitor of translation element (GAIT) suggested 
post-transcriptional regulation that functions to limit or resolve 
inflammation (55, 84). In monocytic cells, IFN-γ can induce 
either pro- or anti-inflammatory responses depending on the 
context. Generally, IFN-γ stimulation induces formation of the 
heterotetrameric GAIT complex in 3′ UTR region, which consists 
of glutamyl-prolyl tRNA synthetase (EPRS), NS1-associated 
protein 1 (NSAP1), ribosomal protein L13a, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). Recent genome-wide 
microarray analysis of IFN-γ-activated monocytic cells identified 
a family of mRNAs encoding multiple chemokine ligands and 
receptors, as candidate GAIT pathway targets (85). Indeed, this 
study revealed the GAIT complex is able to silencing multiple 
transcripts encoding inflammatory molecules (CCL22, CCR3, 
CCR4, and CCR6, and apolipoprotein L2) in L13a-dependent 
manner (85).
The binding activity of RBPs on their target transcript can be 
modulated by cofactors as translational activators or repressors. 
Although literature identifying cofactors in RBPs mediating post-
transcriptional regulation is very poor in monocytic cells, Yu and 
colleague showed that steroid receptor co-activator 3 (SRC3) 
enhanced TIA-1’s repressive effect on TNF-α mRNA translation 
in LPS-stimulated macrophages (86). Moreover, macrophages 
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obtained from SRC3-deficient mice produced significantly more 
proinflammatory cytokines, such as TNF-α, IL-6, and IL-1β, 
than wild-type controls. In light of these observations, SRC-3 can 
repress cytokine production by influencing the binding of TIA-1/
TIAR to ARE-containing transcripts at the mRNA translational 
level in monocytic cells.
RNA editing
RNA editing is one of main categories of RNA modifications that 
code dynamic regulatory information on mRNA and non-coding 
RNA on 5′ and 3′ UTR. Editing is catalyzed by two classes of 
deaminases: those that convert adenosine to inosine (adenosine 
deaminase acting on RNA, ADARs) and those that convert cyto-
sine to uracil (apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide, APOBECs) (58, 59). A-to-I RNA editing can affect 
not only the coding portions of pre-mRNAs but also the non-
coding regions: the 5′- UTRs, the 3′-UTRs and introns. Similar 
with C to U editing by ADARs, APOBECs are also known to 
modify coding portions and 3′ UTR of target transcript sequence. 
Especially, modification on 3′ UTR by ADARs and APOBEC1 
may block miRNA binding, or introduce new miRNA seed target 
sequences, or shift existing targets to sequences that recruit dif-
ferent miRNA (58, 59).
Although little is known about the RNA editing by ADARs 
and Apobec1 in monocytes, it has been hypothesized that 
Apobec-1 mediating RNA editing is associated with post-
transcriptional regulation by RBPs in monocytes. Gene array 
analysis has demonstrated that TIA-1-induced translational 
silencing concomitantly promotes the decay of Apobec1 mRNA 
in peritoneal macrophages (87). In addition to transcriptional 
interaction between TIA-1 and Apobec1, Apobec1 was present 
in TIA-1-positive RNA granules in vitro, indicating that Apobec1 
may participate in the mRNA metabolism alterations mediated 
by RNA granules (88).
DiSeASeS ASSOCiATeD wiTH 
ePiGeNeTiC MODULATiON OF 
MONOCYTiC CeLLS
The mature nervous system is a dynamic and plastic anatomic 
entity comprising multiple cell types that communicate through 
both “hardwiring” and the release of signaling molecules stimu-
lated by local, distant, and external environmental cues. These 
signaling pathways in turn orchestrate the many complex func-
tions needed to pilot the body throughout life and include behav-
ior, learning and memory, reproduction, and immune-mediated 
protection. While such complex functions are developmentally 
established by an anatomic structural blueprint, it is now clear 
that fine-tuning of these communication processes is required at 
every level to adapt to the variability and diversity of cellular or 
external environmental cues.
Epigenetic mechanisms play a major role in generating cell 
type diversity in the CNS by influencing the architecture of 
chromosomes as well as the activation and repression of genetic 
information during critical developmental stages. Genetic 
anomalies affecting various components of epigenetic machinery 
have been shown to induce changes in neural cell identity as well 
as in cognitive and behavioral phenotypes and may underlie the 
pathophysiological diversities observed in the spectrum of neu-
rological diseases. The epigenetic mechanisms as touched upon 
in this review provide a major way for this fine-tuning to occur in 
cells of the mononuclear phagocyte system. While this field is still 
in its infancy, it has evolved enough to require its inclusion in our 
thinking about the etiologies of CNS diseases with regards to epi-
genetic “fine tuning” mechanisms and the cumulative, long range 
consequences they may have when they become “dysfunctional.”
When you want to understand a mechanism, study a 
disease – Robert Good (circa 1985)
There are several reports in the literature related to cells of the 
monocytic lineage that have opened the door to new understand-
ing of epigenetic mechanisms underlying some disease states 
of the CNS. We now recognize two new factors that lead us to 
reconsider the phenotypic and functional heterogeneity of cells 
previously referred to as “microglia”: (i) leukocytes, monocytes, 
in particular, readily have access to the CNS and can carry out 
immune functions of surveillance and tolerance in the steady 
state (4) and (ii) the origin and immune role of the “microglia” 
has become less clear in the steady state and following neuronal 
damage (89–92).
In addition to the better studied epigenetic processes (DNA 
methylation, histone modifications), which are postulated 
to dynamically transduce environmental inputs into lasting 
physiological and behavioral changes, we propose that the epi-
transcriptomic process of RNA editing in response to stimuli as 
diverse as stress, infection, or hormonal stimulation may be the 
bases of cellular and functional diversity seen within the cells of 
monocytic lineage in the CNS and beyond.
Both ADAR-mediated and APOBEC-mediated RNA editing 
events have been cataloged from a variety of tissues, including 
cells of the monocytic lineage (93). Within the populations of 
cells of the monocytic lineage, robust editing has been detected 
from RNA-seq data in hundreds of distinct transcripts, but edit-
ing rates vary widely (from under 1% to almost 100%). This range 
of editing rates could either result from approximately equal rates 
of editing within each individual cell in the population, or could 
instead correspond to an average of distinct, variable editing 
signatures across individual cells in the population. Our recent 
data explicitly support the hypothesis that RNA editing generates 
diverse cellular populations with distinct signatures Harjanto 
et al., in revision. Thus, editing-mediated RNA-level sequence 
diversity may contribute to the functional heterogeneity apparent 
in immune cell populations at steady state.
Direct reports of epigenetic events associated with the brain 
function or pathology have been carried out for the most part on 
selected human postmortem CNS tissue, which lend to experimen-
tal difficulties in the execution and interpretations of the data. The 
clearest reports of epigenetic RNA editing associated with brain 
function have been limited to selected regions of the CNS rather 
than on any specific cell type. Gaisler-Solomon et al. have shown 
A-to-I editing, which is catalyzed by ADAR2, to occur at the Q/R 
site of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
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acid (AMPA) glutamate receptor subunit GluA2 (94). Changes 
leading to the reduction of editing at this site led to abnormal 
calcium fluxes and cell death. Examination of hippocampal tissue 
derived from AD patients showed marked decrease in editing 
events at the GluA2 site compared to control tissue. This effect 
was also seen in tissue derived from subjects carrying the apolipo-
protein E4 allele regardless of their clinical diagnosis. In addition, 
ADAR2 mRNA was reported to be decreased in the AD caudate 
tissue, which collectively suggested to these authors that changes 
in these editing events correlates with neurodegenerative disease. 
These data are in line with previous reports (95–98), suggesting 
that ADAR2-dependent GluR2/GluA2 editing sites in neurons 
may be vulnerable to pathological states. Although in these 
studies neurons were shown to be the site of editing of AMPA 
receptor subunit, monocytic cells isolated from glioblastomas 
have also known to express and upregulate the expression of 
GRIA2 (GluA2 or AMPA receptor 2) (99). While not investigated, 
it is entirely possible that these monocytic cells may also edit the 
GluA2 subunit via this pathway, which may be a contributing 
factor in the neurobiology of this CNS disease.
Baysal et  al. (100) have shown that C-to-U RNA editing of 
(C136U, R46X) in monocytes by APOBEC1 inactivates a small 
fraction of succinate dehydrogenase (SDH; mitochondrial complex 
II) subunit B (SDHB) mRNAs in normal steady-state peripheral 
blood mononuclear cells. Mutations in SDH, a heterotetrameric 
tumor suppressor complex, cause paraganglioma tumors that are 
associated with activation of hypoxia inducible pathways. This 
study found that C–U editing was down regulated in mRNA of 
this peptide during hypoxia events, specifically suggesting C–U 
editing by APOBEC1 helps monocytes to adapt to hypoxic con-
ditions and more broadly suggests that C-to-U recoding of the 
RNA of certain genes is dynamically induced by physiologically 
relevant environmental factors. Most recently, these data have 
been extended to human monocytes. Sharma et  al. (93) have 
demonstrated that C–U RNA editing by APOBEC3A (cytidine 
deaminase) of innate restriction factors occurs in macrophages 
during M1 polarization as well as in monocytes in response to 
hypoxia and interferons.
Studies from our laboratories show that RNA editing by 
APOBEC1 in bone marrow-derived mouse macrophages lead to 
the generation of populations that are heterogeneous and func-
tionally diverse, enabling rapid population adaption in different 
environmental settings. We have further demonstrated in  vivo 
using the BV2 microglia cell line and ex vivo using wildtype and 
APOBEC1 knockout mouse that APOBEC 1 catalyzed editing 
occurs in brain cells of monocytic lineage. Additionally, we have 
shown that APOBEC1 in brain-derived monocytes is targeted by 
a rhabdovirus to maintain an intracellular, steady-state environ-
ment in order to utilize its cellular machinery and facilitate viral 
replication Chung et al., under review.
It has been shown that editing rates tend to increase with 
increased expression of the cognate enzyme (101). Expression of 
both editing enzymes increases under inflammatory conditions 
(101, 102) and in the cases described thus far (in the context of 
cancer) increased editing correlates with increased progression 
and poor prognosis (101, 102). In light of these reports, we can 
hypothesize that editing enzymes may play critical role in the 
etiology of CNS diseases, many of which are associated with 
inflammatory conditions. We believe that a better understanding 
of the functional outcomes of epigenetic modifications, such as 
RNA editing, and of diseases specifically associated with hyper- 
or hypo-editing will be of substantial interest in many neuro-
pathologies of unknown etiologies which show significant “weak 
or missing heritability” at the genetic level, but which clearly have 
a strong genetic component.
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